Issue 11, 2024

Correction: computational design, synthesis, and assessment of 3-(4-(4-(1,3,4-oxadiazol-2-yl)-1H-imidazol-2-yl)phenyl)-1,2,4-oxadiazole derivatives as effective epidermal growth factor receptor inhibitors: a prospective strategy for anticancer therapy

Abstract

Correction for ‘Computational design, synthesis, and assessment of 3-(4-(4-(1,3,4-oxadiazol-2-yl)-1H-imidazol-2-yl)phenyl)-1,2,4-oxadiazole derivatives as effective epidermal growth factor receptor inhibitors: a prospective strategy for anticancer therapy’ by Nilesh Raghunath Khedkar et al., RSC Med. Chem., 2024, 15, 1626–1639, https://doi.org/10.1039/D4MD00055B.

Associated articles

Article information

Article type
Correction
Submitted
08 Oct 2024
Accepted
08 Oct 2024
First published
15 Oct 2024
This article is Open Access
Creative Commons BY license

RSC Med. Chem., 2024,15, 3912-3912

Correction: computational design, synthesis, and assessment of 3-(4-(4-(1,3,4-oxadiazol-2-yl)-1H-imidazol-2-yl)phenyl)-1,2,4-oxadiazole derivatives as effective epidermal growth factor receptor inhibitors: a prospective strategy for anticancer therapy

N. R. Khedkar, M. Sindkhedkar and A. Joseph, RSC Med. Chem., 2024, 15, 3912 DOI: 10.1039/D4MD90040E

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements